[Congressional Record Volume 157, Number 11 (Wednesday, January 26, 2011)]
[House]
[Page H504]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]
SUPPORT BIOMEDICAL RESEARCH
The SPEAKER pro tempore. Under a previous order of the House, the
gentleman from New York (Mr. Higgins) is recognized for 5 minutes.
Mr. HIGGINS. Mr. Speaker, last night the President spoke to Congress
and to the Nation about the need for increased funding for biomedical
research, both to improve the quality of life of our Nation's citizens,
and to generate new economic investment. He is right, and we must heed
his call on this initiative.
Cancer research is a vital part of our Nation's biomedical research
enterprise, but our Federal commitment to this promising field has not
kept up with the rapid place of scientific innovation. In fact, when
you take into account medical inflation, our funding commitment to the
National Cancer Institute and the National Institutes of Health has
actually been cut over the past 7 years. We can, and must, do better.
We will only see new, promising cancer therapies that increase
survival and life quality through a sustained, multi-year commitment of
Federal funding for cancer research. There is only one failure in
cancer research. It's when you quit or you're forced to quit because of
lack of funding. When Federal cancer funding is cut or not sustained
over the long term, we lose not only promising cancer research, but we
also lose talented cancer researchers.
President Nixon recognized this 40 years ago when he signed the
National Cancer Act. At that time, less than 50 percent of cancer
patients lived 5 years beyond their diagnosis. Today, with advances in
early detection, healthy lifestyles, and new cancer therapies, the
survival rate is 65 percent for adults and 80 percent for kids. That
would not have happened without a significant investment in Federal
research funding. The National Cancer Act led to a continued, sustained
investment in cancer research that funded the research community to
develop a new generation of smart drugs that help thousands of cancer
patients every single day.
Smart drugs are highly targeted to attack fast-growing cancer cells
without damaging healthy cells. Drugs like herceptin for breast cancer,
avastin for lung cancer, gleevec for gastrointestinal stromal tumors
inhibit or block cancer cell growth. In fact, less than 10 percent of
cancer deaths are attributed to the original tumor. It's when cancer
metastasizes, when it grows, when it advances to a vital organ the
cancer becomes lethal.
All this could not be more important to the community that I serve in
western New York. Buffalo, New York, gave the Nation and the world
cancer research when the New York State Cancer Laboratory was first
established by Dr. Roswell Park in 1897. Roswell Park Cancer Institute
continues that mission today. And the research put out by doctors has
led to many breakthroughs that alleviate suffering due to cancer every
single day.
Roswell Park is one of 40 National Cancer Institute-designated
comprehensive cancer centers around the country that are the engine for
our Nation's war on cancer. An important part of Buffalo and western
New York's future relies upon the success of research completed at
Roswell and companies at the Buffalo Niagara Medical Campus coming to
market, creating new small businesses, and high-quality jobs. If we
don't have a sustained investment in cancer research moving forward,
the promise of that research and the jobs it will create will be lost.
The time to act is now. Cancer is estimated to cost our Nation $263
billion in 2010 alone, according to the National Institutes of Health.
Mr. Speaker, I urge my colleagues to support a renewed commitment to
cancer research because there is no better time than now. Alleviating
suffering and death due to cancer in our lifetime should not only be
Congress's goal; it should be America's goal. And we should insist on a
huge Federal investment toward that goal.
____________________